{"id":1655,"date":"2025-04-03T19:28:25","date_gmt":"2025-04-03T19:28:25","guid":{"rendered":"https:\/\/incirrata.se\/?p=1655"},"modified":"2025-04-10T19:50:16","modified_gmt":"2025-04-10T19:50:16","slug":"xvivo-in-i-modellportfolj-opportunity","status":"publish","type":"post","link":"https:\/\/incirrata.se\/en\/xvivo-in-i-modellportfolj-opportunity\/","title":{"rendered":"Xvivo into Model Portfolio Opportunity"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"1655\" class=\"elementor elementor-1655\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-488f9c33 e-flex e-con-boxed e-con e-parent\" data-id=\"488f9c33\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1dbc4514 elementor-widget elementor-widget-text-editor\" data-id=\"1dbc4514\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t\n<p>After a really weak start to the year for&nbsp;<strong>Xvivo Perfusion&nbsp;<\/strong>(-40%), without any clear corporate event motivating the development, we now include the stock in the Model Portfolio Opportunity. &nbsp;<\/p>\n\n\n\n<p><strong>Strong technology in a growing market<\/strong><br>XVIVO Perfusion is a leader in organ preservation, with a technology that doubles the time lungs can be kept fresh for transplantation \u2013 from under 5 to over 10 hours \u2013 improving logistics, organ utilization and survival. Lung transplants in the US are growing, and the company is well positioned to capture market share. Although Q1 is expected to show subdued growth compared to the previous year, it is historically a weak quarter and comparative figures are high.<\/p>\n\n\n\n<p><strong>Strong future prospects with new organs in the pipeline<\/strong><br>The company has already achieved two important milestones for 2025: Continued Access Approval (CAP) for the heart technology in the US and record-breaking approval to start a liver study. This opens up new revenue streams as early as Q2. Sales are expected to increase significantly in 2025\u20132027, and the company has the potential to reach its long-term EBITDA margin of 30 %. Cash flow is positive and investments are focused on building the sales team in the US.<\/p>\n\n\n\n<p><strong>Unattractive price development opens up opportunities<\/strong><br>The stock has fallen 40% % so far this year without any negative news, which creates an attractive position to include the company in our model portfolio. Two important triggers lie ahead: a potential CE approval in Europe for the heart technology, and new study data from the European heart study to be presented in Boston in April. We believe that the market is undervaluing the company&#039;s long-term potential. The company is not cheap but is growing nicely with good profitability. The stock is now trading at EV\/EBIT 50x 2025e, 30x 2026e and 20x 2027e.<\/p>\n\n\n\n<p>I can highly recommend the interview the CEO did with the Paretopodden recently.&nbsp;<a href=\"https:\/\/podcasts.apple.com\/se\/podcast\/b%C3%B6rsm%C3%A4klarna\/id1755582652?i=1000701001430\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/podcasts.apple.com\/se\/podcast\/b%C3%B6rsm%C3%A4klarna\/id1755582652?i=1000701001430<\/a><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"922\" height=\"788\" src=\"https:\/\/incirrata.se\/wp-content\/uploads\/2025\/04\/xvivo.png\" alt=\"\" class=\"wp-image-1703\" srcset=\"https:\/\/incirrata.se\/wp-content\/uploads\/2025\/04\/xvivo.png 922w, https:\/\/incirrata.se\/wp-content\/uploads\/2025\/04\/xvivo-300x256.png 300w, https:\/\/incirrata.se\/wp-content\/uploads\/2025\/04\/xvivo-768x656.png 768w, https:\/\/incirrata.se\/wp-content\/uploads\/2025\/04\/xvivo-14x12.png 14w\" sizes=\"(max-width: 922px) 100vw, 922px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"946\" height=\"810\" src=\"https:\/\/incirrata.se\/wp-content\/uploads\/2025\/04\/xvivo2.png\" alt=\"\" class=\"wp-image-1704\" srcset=\"https:\/\/incirrata.se\/wp-content\/uploads\/2025\/04\/xvivo2.png 946w, https:\/\/incirrata.se\/wp-content\/uploads\/2025\/04\/xvivo2-300x257.png 300w, https:\/\/incirrata.se\/wp-content\/uploads\/2025\/04\/xvivo2-768x658.png 768w, https:\/\/incirrata.se\/wp-content\/uploads\/2025\/04\/xvivo2-14x12.png 14w\" sizes=\"(max-width: 946px) 100vw, 946px\" \/><\/figure>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-81f6237 e-flex e-con-boxed e-con e-parent\" data-id=\"81f6237\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d905da2 elementor-widget elementor-widget-html\" data-id=\"d905da2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<!-- TradingView Widget BEGIN -->\n<div class=\"tradingview-widget-container\" style=\"height:100%;width:100%\">\n  <div class=\"tradingview-widget-container__widget\" style=\"height:calc(100% - 32px);width:100%\"><\/div>\n  <div class=\"tradingview-widget-copyright\"><a href=\"https:\/\/www.tradingview.com\/\" rel=\"noopener nofollow\" target=\"_blank\"><span class=\"blue-text\">Track all markets on TradingView<\/span><\/a><\/div>\n  <script type=\"text\/javascript\" src=\"https:\/\/s3.tradingview.com\/external-embedding\/embed-widget-advanced-chart.js\" async>\n  {\n  \"autosize\": true,\n  \"symbol\": \"OMXSTO:XVIVO\",\n  \"interval\": \"D\",\n  \"timezone\": \"Etc\/UTC\",\n  \"theme\": \"dark\",\n  \"style\": \"1\",\n  \"locale\": \"en\",\n  \"allow_symbol_change\": true,\n  \"support_host\": \"https:\/\/www.tradingview.com\"\n}\n  <\/script>\n<\/div>\n<!-- TradingView Widget END -->\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Efter en riktigt svag start p\u00e5 \u00e5ret f\u00f6r&nbsp;Xvivo Perfusion&nbsp;(-40%), utan n\u00e5gon tydlig bolagsh\u00e4ndelse som motiverar utvecklingen, tar vi nu in aktien i Modellportf\u00f6lj Opportunity. &nbsp; Stark teknik i v\u00e4xande marknadXVIVO Perfusion \u00e4r ledande inom organpreservation, med en teknologi som f\u00f6rdubblar tiden lungor kan h\u00e5llas fr\u00e4scha inf\u00f6r transplantation \u2013 fr\u00e5n under 5 till \u00f6ver 10 timmar [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1705,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-1655","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-update"],"_links":{"self":[{"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/posts\/1655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/comments?post=1655"}],"version-history":[{"count":10,"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/posts\/1655\/revisions"}],"predecessor-version":[{"id":1729,"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/posts\/1655\/revisions\/1729"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/media\/1705"}],"wp:attachment":[{"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/media?parent=1655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/categories?post=1655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/incirrata.se\/en\/wp-json\/wp\/v2\/tags?post=1655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}